SCHEMBL25572011

SCHEMBL25572011

COCC1OC(C)C(F)C1OP(=O)(O)OC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13882147 0.95 FBP1 (0.30) —
SCHEMBL25553231 0.89 — —
SCHEMBL27282032 0.88 SMPD1 (0.36) —
SCHEMBL25553232 0.86 FBP1 (0.30) —
SCHEMBL25485097 0.84 — —
SCHEMBL16389193 0.84 — —
SCHEMBL15905930 0.84 — —
SCHEMBL16389194 0.84 — —
SCHEMBL25572013 0.84 — —
SCHEMBL20465720 0.84 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240238435-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2024-07-18 — — US disclosed
US-20240209119-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES DYNE THERAPEUTICS, INC. (US) 2024-06-27 — — US disclosed
US-20240066140-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2024-02-29 — — US disclosed
US-20240016952-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2024-01-18 — — US disclosed
US-11839660-B2 Anti-transferrin receptor antibody and uses thereof DYNE THERAPEUTICS, INC. (US) 2023-12-12 — — US disclosed
US-20230346967-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES DYNE THERAPEUTICS, INC. (US) 2023-11-02 — — US disclosed
US-20230346966-A1 MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY DYNE THERAPEUTICS, INC. (US) 2023-11-02 — — US disclosed
US-20230330562-A1 METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES DYNE THERAPEUTICS, INC. (US) 2023-10-19 — — US disclosed
US-20230330247-A1 MUSCLE TARGETING COMPLEXES AND FORMULATIONS FOR TREATING MYOTONIC DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2023-10-19 — — US disclosed
US-20230321264-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2023-10-12 — — US disclosed
US-20230285586-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES DYNE THERAPEUTICS, INC. (US) 2023-09-14 — — US disclosed
US-20230285582-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2023-09-14 — — US disclosed
US-20230256113-A1 ANTI-TRANSFERRIN RECEPTOR ANTIBODY AND USES THEREOF DYNE THERAPEUTICS, INC. (US) 2023-08-17 — — US disclosed
US-20230226212-A1 MUSCLE-TARGETING COMPLEXES AND USES THEREOF DYNE THERAPEUTICS, INC. (US) 2023-07-20 — — US disclosed
US-20230203180-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR MODULATION OF GENES ASSOCIATED WITH MUSCLE HEALTH DYNE THERAPEUTICS, INC. (US) 2023-06-29 — — US disclosed
US-11679161-B2 Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy DYNE THERAPEUTICS, INC. (US) 2023-06-20 — — US disclosed
US-11672872-B2 Anti-transferrin receptor antibody and uses thereof DYNE THERAPEUTICS, INC. (US) 2023-06-13 — — US disclosed
US-11648318-B2 Anti-transferrin receptor (TFR) antibody and uses thereof DYNE THERAPEUTICS, INC. (US) 2023-05-16 — — US disclosed
US-20230144436-A1 MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING MYOTONIC DYSTROPHY DYNE THERAPEUTICS, INC. (US) 2023-05-11 — — US disclosed
US-11638761-B2 Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy DYNE THERAPEUTICS, INC. (US) 2023-05-02 — — US disclosed
Send feedback